MX2013006140A - Uso de ligandos sigma en dolor por cancer de huesos. - Google Patents

Uso de ligandos sigma en dolor por cancer de huesos.

Info

Publication number
MX2013006140A
MX2013006140A MX2013006140A MX2013006140A MX2013006140A MX 2013006140 A MX2013006140 A MX 2013006140A MX 2013006140 A MX2013006140 A MX 2013006140A MX 2013006140 A MX2013006140 A MX 2013006140A MX 2013006140 A MX2013006140 A MX 2013006140A
Authority
MX
Mexico
Prior art keywords
bone cancer
cancer pain
sigma ligands
sigma
ligands
Prior art date
Application number
MX2013006140A
Other languages
English (en)
Other versions
MX343773B (es
Inventor
Jose Miguel Vela-Hernandez
Daniel Zamanillo-Castanedo
Carlos Plata-Salaman
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of MX2013006140A publication Critical patent/MX2013006140A/es
Publication of MX343773B publication Critical patent/MX343773B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compression, Expansion, Code Conversion, And Decoders (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La invención se refiere al uso de un ligando sigma, particularmente un ligando sigma de fórmula (I) para prevenir y/o tratar dolor asociado a cáncer de huesos.
MX2013006140A 2010-12-03 2011-12-02 Uso de ligandos sigma en dolor por cancer de huesos. MX343773B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10382330A EP2460519A1 (en) 2010-12-03 2010-12-03 Use of sigma ligands in bone cancer pain
PCT/EP2011/071584 WO2012072782A1 (en) 2010-12-03 2011-12-02 Use of sigma ligands in bone cancer pain

Publications (2)

Publication Number Publication Date
MX2013006140A true MX2013006140A (es) 2013-07-03
MX343773B MX343773B (es) 2016-11-23

Family

ID=43629676

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006140A MX343773B (es) 2010-12-03 2011-12-02 Uso de ligandos sigma en dolor por cancer de huesos.

Country Status (33)

Country Link
US (1) US20130324535A1 (es)
EP (2) EP2460519A1 (es)
JP (1) JP6027014B2 (es)
KR (1) KR101855358B1 (es)
CN (1) CN103313709B (es)
AR (1) AR084730A1 (es)
BR (1) BR112013013369A8 (es)
CA (1) CA2819442C (es)
CO (1) CO6781549A2 (es)
CY (1) CY1119030T1 (es)
DK (1) DK2646025T3 (es)
ES (1) ES2626672T3 (es)
HR (1) HRP20170818T1 (es)
HU (1) HUE033488T2 (es)
IL (1) IL226706A (es)
LT (1) LT2646025T (es)
MA (1) MA34878B1 (es)
ME (1) ME02852B (es)
MX (1) MX343773B (es)
MY (1) MY171994A (es)
NZ (1) NZ612119A (es)
PL (1) PL2646025T3 (es)
PT (1) PT2646025T (es)
RS (1) RS56081B1 (es)
RU (1) RU2585095C2 (es)
SG (1) SG190745A1 (es)
SI (1) SI2646025T1 (es)
TN (1) TN2013000227A1 (es)
TR (1) TR201708567T4 (es)
TW (1) TWI629060B (es)
UA (1) UA112638C2 (es)
WO (1) WO2012072782A1 (es)
ZA (1) ZA201304966B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2426111A1 (en) * 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2792352A1 (en) 2013-04-16 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Alpha-2 adrenoreceptor and sigma receptor ligand combinations
EP2818166A1 (en) * 2013-06-26 2014-12-31 Laboratorios del Dr. Esteve S.A. Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS)
TN2016000084A1 (en) * 2013-09-12 2017-07-05 Esteve Labor Dr Nsaid and sigma receptor ligand combinations
JP2016540771A (ja) 2013-12-17 2016-12-28 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ セロトニン−ノルアドレナリン再取り込み阻害薬（ｓｎｒｉ）およびシグマ受容体リガンドの組み合わせ
SG11201604478UA (en) 2013-12-17 2016-07-28 Esteve Labor Dr Gabapentinoids and sigma receptor ligands combinations
EP2929883A1 (en) * 2014-04-08 2015-10-14 Institut Pasteur Pyrazole derivatives as dihydroorotate dehydrogenase (DHODH) inhibitors
ES2701975R1 (es) * 2016-07-12 2019-03-01 Esteve Pharmaceuticals Sa Uso de ligandos del receptor sigma en el dolor post-herpetico
US11975055B2 (en) * 2018-05-21 2024-05-07 Ipsen Biopharm Limited Suppression of bone cancer-induced allodynia
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE
CN112341397B (zh) * 2019-08-09 2023-05-23 成都苑东生物制药股份有限公司 吡嗪类衍生物或盐、异构体、其制备方法及用途
KR20210151572A (ko) 2020-06-05 2021-12-14 주식회사 허밍아비스 발열체 조성물 및 이를 이용한 마스크 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1641764T3 (da) * 2003-06-26 2011-11-21 Novartis Ag P38-kinasehæmmere på grundlag af 5-leddede heterocykliske forbindelser
JP5139061B2 (ja) * 2004-08-27 2013-02-06 ラボラトリオス デル ドクトール エステベ エセ．ア． シグマ受容体阻害剤
SI1781618T1 (sl) * 2004-08-27 2013-01-31 Laboratorios Del Dr. Esteve, S.A. Inhibitorji sigma receptorja
CA2641144A1 (en) * 2006-03-01 2007-09-07 Rosa Cuberes-Altisent Pyrazole derivatives as sigma receptor inhibitors
EP2113501A1 (en) * 2008-04-25 2009-11-04 Laboratorios Del. Dr. Esteve, S.A. 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors
EP2116539A1 (en) * 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353591A1 (en) * 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof

Also Published As

Publication number Publication date
LT2646025T (lt) 2017-06-12
NZ612119A (en) 2014-06-27
JP2014501732A (ja) 2014-01-23
EP2646025B1 (en) 2017-03-15
MY171994A (en) 2019-11-11
US20130324535A1 (en) 2013-12-05
PL2646025T3 (pl) 2017-09-29
MX343773B (es) 2016-11-23
IL226706A (en) 2015-07-30
BR112013013369A8 (pt) 2018-01-09
MA34878B1 (fr) 2014-02-01
ZA201304966B (en) 2014-09-25
CA2819442A1 (en) 2012-06-07
AU2011334880A1 (en) 2013-07-11
KR101855358B1 (ko) 2018-05-04
TWI629060B (zh) 2018-07-11
JP6027014B2 (ja) 2016-11-16
AU2011334880B2 (en) 2016-09-15
HUE033488T2 (en) 2017-12-28
UA112638C2 (uk) 2016-10-10
TR201708567T4 (tr) 2019-01-21
EP2646025A1 (en) 2013-10-09
RU2585095C2 (ru) 2016-05-27
TN2013000227A1 (en) 2014-11-10
CO6781549A2 (es) 2013-10-31
TW201249805A (en) 2012-12-16
CN103313709A (zh) 2013-09-18
EP2460519A1 (en) 2012-06-06
SG190745A1 (en) 2013-07-31
RS56081B1 (sr) 2017-10-31
CA2819442C (en) 2018-06-12
DK2646025T3 (en) 2017-06-06
ES2626672T3 (es) 2017-07-25
ME02852B (me) 2018-04-20
WO2012072782A1 (en) 2012-06-07
BR112013013369A2 (pt) 2016-09-06
HRP20170818T1 (hr) 2017-08-25
SI2646025T1 (sl) 2017-07-31
CY1119030T1 (el) 2018-01-10
RU2013130222A (ru) 2015-01-10
CN103313709B (zh) 2017-05-24
KR20130135881A (ko) 2013-12-11
AR084730A1 (es) 2013-06-05
PT2646025T (pt) 2017-06-26

Similar Documents

Publication Publication Date Title
TN2013000227A1 (en) Use of sigma ligands in bone cancer pain
AU2011328009A8 (en) Compounds and methods for treating pain
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
MX350828B (es) Uso de ligandos sigma en la hiperalgesica inducida por opioides.
TN2013000508A1 (en) Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
MX2013006392A (es) Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1.
EA201171367A1 (ru) Винилиндазолильные соединения
SG10201903119QA (en) Polypeptide vaccine
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
EA201400178A1 (ru) Лечение рака молочной железы
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
TN2013000460A1 (en) Use of sigma ligands in diabetes type-2 associated pain
PH12015501088A1 (en) Dimeric compounds
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
PH12016501095A1 (en) Gabapentinoids and sigma receptor ligands combinations
PH12015502815A1 (en) Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (ic/bps)
MX2013002155A (es) Compuestos para el tratamiento de cancer.
MX359181B (es) Hidrolizado de colágeno y uso del mismo.
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
ZA201209452B (en) Gold complexes for use in the treatment of cancer
MX365192B (es) Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer.
MX2011006532A (es) Compuestos anticancerigenos.
TN2012000552A1 (en) An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
TN2013000026A1 (en) Use of sigma ligands in opioid - induced hyperalgesia

Legal Events

Date Code Title Description
FG Grant or registration